-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
O.Mousa--SF-PST